|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 第二次中国临床血脂控制达标率及影响因素多中心协作研究显示文摘目的了解我国临床血脂控制的最新现状,指导临床血脂异常防治实践。方法在全国21家省部级医院和6家地县级医院中,查阅2004年1月1日至2006年2月28日间开始服调脂药物,且同一药物同一剂量维持≥2个月的2237名患者病例资料,依据美国2004年国家胆固醇教育计划(NCEP)成人治疗组第三次报告(ATPBⅢ)及《中国成人血脂异常防治指南》标准计算血脂控制达标率。结果 (1)在符合任一血脂防治建议/指南的药物起始治疗标准的2094例患者中,80%来自省部级医院,60%为60岁以上,57%有胆固醇升高,15%无血脂异常,68%合并冠心病等动脉粥样硬化性疾病,75%合并高血压,80%为高危和极高危患者,84%使用他汀类药物,83%采取了不同程度的饮食治疗。(2)依据美国2004年 NCEP ATPⅢ最新报告,总达标率为34%,低危组、中危组、中高危组、高危组和极高危组达标率分别为85%、78%、61%、3 1%和22%,差异有统计学意义(趋势性检验 P<0.001);依据我国新的《成人血脂异常防治指南》,总达标率为50%,低危组、中危组、高危组和极高危组达标率分别为91%、77%、49%和38%,组间差异及趋势性检验均有统计学意义(P<0.001)。(3)联合用药者达标率为51%,单用他汀类35%,贝特类23%,烟酸类24%,其他类28%,组间差异有统计学意义(P<0.001)。(4)对1808例服用他汀类药物患者的多元 logistic 回归分析表明,他汀类药物剂量(高剂量比低剂量,OR=1.72,95%CI:1.15~2.58)、危险分层(极高危比低危,OR=0.02,95%CI:0.01~0.03)、基线 LDL-C[每升高0.259 mmol/L(10 mg/dl),OR=0.83,95%CI:0.80~0.86]和性别(女性比男性,OR=0.77,95%CI:0.60~0.99)等是影响达标率的主要因素。结论我国目前调脂药物的应用对象发生了很大变化,调脂治疗的目的已不单纯是为了降低胆固醇。临床血脂控制状况与各防治指南要求相距仍甚远,特别是高危和极高危患者。要进一步改善我国临床血脂控制状况,药物种类、药物剂量、联合治疗和治疗性生活方式改变等多方面均需要进一步提高。 | The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China | 2007 | 中华心血管病杂志2007，35，5： | 127 |
| 2 | 尿激酶治疗急性心肌梗塞多中心临床试验1406例总结显示文摘为观察尿激酶天普洛欣(UKTP)经静脉溶栓治疗急性心肌梗塞(AMI)的临床有效性及安全性。收集协作组148家医院1994年11月至1996年4月经静脉UKTP溶栓治疗AMI患者1406例,观察临床疗效、副作用及病死率等。其中124例行90分钟冠状动脉造影评价梗塞血管开通情况。结果:梗塞血管临床再灌注率为73.5%,90分钟冠状动脉造影血管开通率为72.6%,5周总病死率为7.8%(109/1406),轻度出血10.2%(143/1406),中重度出血0.43%(6/1406),脑出血0.50%(7/1406)。老年(>65岁)甚至高龄(>75岁)患者溶栓及距发病超过6小时者,其用药仍然安全有效,UKTP合适的用药剂量可能为150万U左右。结果提示UKTP治疗AMI安全有效。 | The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020) | 1997 | 中华心血管病杂志1997，25，3： | 139 |
| 3 | 急性病毒性心肌炎的药物治疗观察显示文摘目的 全国十二家大型医院协作观察中西医结合治疗急性病毒性心肌炎疗效。方法 对 10 2 8例临床诊断为急性病毒性心肌炎患者随机各分两组 ,治疗组 60 2例 ,用中西医结合 (黄芪、牛磺酸、泛葵利酮、抗心律失常药等)治疗 ;对照组 4 2 6例 ,用常规 (极化液、抗心律失常药等 )治疗。结果 中西医结合治疗组临床症状改善、外周血肠道病毒阴转、心电图ST T改变及房室传导阻滞、阵发性心房颤动、窦房传导阻滞等恢复均优于对照组(P <0 .0 1、0 .0 5 ) ;对早搏及心功能改善两组间无统计学差异(P <0 .0 5 )。结论 在目前对急性病毒性心肌炎无特效药物治疗的情况下 ,采用中西医结合治疗可作为一种治疗手段。 | Collaborative Group of “Key National Medical Projects for the Ninth Five Year Plan Research” (Correspondence: YANG Yingzhen, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital,Shanghai Medical University,Shanghai 200032) | 1999 | 中华心血管病杂志1999，27，6： | 94 |
| 4 | POST-STROKE ANTIHYPERTENSIVE TREATMENT STUDY A PRELIMINARY RESULT显示文摘Post-stroke Antihypertensive Treatment Study (PATS) was a randomized, double-blind and placebo-controlled trial, which aimed at determining whether antihypertensive treatment could reduce the risk of fatal and nonfatal stroke incidence in patients with a history of stroke or transient ischemic attack (TLA). 5 665 patients were randomized by a sealed envelope system. Systolic blood pressure (SBP) ranged from 80 to 280 mm Hg and diastolic (DBP) from 50 to 150 mmHg. The average SBP was 154 mmHg and average DBP 93 mmHg. The mean age was 60 years. Among the patients, women accounted for 28%. In 71% the latest stroke was ischemic. Average follow-up approximated to 2 years. The three-year average SBP was 149 mmHg for the placebo group and 144 mmHg for the indapamide treatment group, and the three-year DBP was 89 mmHg and 87 mmHg respectively. The three-year first incidence of fatal and nonfatal stroke was 12.3 per 100 patients placebo treatment and 9.4 per 100 with indapamide. The relative risk by | PATS Collaborating Group | 1995 | Chinese Medical Journal1995，，9： | 94 |
| 5 | 不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究显示文摘目的 观察不同抗栓方案对急性冠状动脉综合征心脏事件、出血风险和预后的影响。方法 本研究为前瞻性、多中心、随机、开放试验 ,入选患者随机分为静脉滴注普通肝素组和皮下注射低分子量肝素组。入选对象为不稳定性心绞痛或非Q波心肌梗死 ,入选前 4 8小时以内至少有一次心绞痛发作 ,ST段无抬高。肝素 10 0IU/kg静注 ,续 10 0 0IU/h ,维持活化的部分凝血活酶时间 (APTT)或活化的全血凝固时间 (ACT)于正常的 1 5~ 2 0倍 ,连续 7日。低分子量肝素 0 4~ 0 6ml,每日两次皮下注射 ,连续 7日。主要观察终点 :随访治疗 3 0日内发生急性心肌梗死、心脏性或非心脏性死亡和药物治疗无法控制心绞痛 ,需行急性血运重建术。住院至少 7日 ,随访至治疗后 3 0日。结果 本研究共入选符合条件的患者 4 0 2例 ,两组在性别、年龄、心血管危险因素和心绞痛发作方面差异无显著性。治疗后 7日 ,两组用药期间平均胸痛发作次数差异无显著性 ,但肝素组有更多的患者需口服硝酸甘油缓解胸痛 ;病死率在低分子量肝素组较普通肝素组低 ,两组比较P值为 0 0 62 ,复合终点事件 (死亡、心肌梗死和紧急血管重建 )在低分子量肝素组明显下降。低分子量肝素组出血事件明显少于肝素组。治疗开始后 3 0日 ,低分子量肝素组死亡和复合终点事? | Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China) | 2000 | 中华心血管病杂志2000，28，1： | 172 |
| 6 | 急性心肌梗死尿激酶溶栓治疗开始时间对疗效的影响显示文摘目的:为探讨治疗在急性心肌梗死(AMI)发病后各不同时间开始用尿激酶(静脉法)对疗效的影响。方法:37所协作医院收治的AMI患者1138例按统一的治疗方案应用尿激酶,血管再通采用统一的临床间接指标标准判定。比较发病后不同时间开始用药患者的血管再通率和4周病死率。结果:发病后2小时内、2~4小时内、4~6小时内和6~12小时开始用尿激酶的患者分别为128例、461例、434例和115例。其血管再通率分别为71.9%、70.1%、63.6%和40.0%;4周病死率分别为7.0%、6.5%、12.2%和13.9%。发病后2小时内和2~4小时内组血管再通率与4周病死率均无统计学差异,故合并为4小时内组,与4~6小时内组和6~12小时组比较,血管再通率(70.5%)都显著高于后两组,P均<0.001;4周病死率(6.6%)都明显低于后两组,P均<0.01。4~6小时内组与6~12小时组比较:血管再通率前者显著高于后者,P<0.001;4周病死率无显著性差异。 | Collaborative Research Group of National“Eighth Five year”Project(85 915 02 01) (Fu Wai Hospital,CAMS and PUMC,Beijing 100037) | 1996 | 中国循环杂志1996，11，7： | 47 |
| 7 | 重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验显示文摘目的研究新型溶栓剂——重组葡激酶(r-Sak)治疗急性心肌梗死(AMI)的冠状动脉通畅率、临床疗效及安全性。方法本研究为多中心、随机、平行对照临床试验,入选发病12 h 内、年龄≤70岁、ST 段抬高的 AMI 患者,随机分为 r-Sak 组104例,给予 r-Sak 3 mg 静注,12 mg 于30 min 内静脉输注,总量15 mg;重组组织型纤溶酶原激活剂(rt-PA)组106例,8 mg 静注,42 mg 在90 min 内输注,总量50 mg。全部患者给予阿司匹林和静脉输注肝素,于用药90 min 行冠状动脉造影,对 TIMI 血流0~2级者行补救性 PCI。结果主要终点:用药90 min 冠状动脉通畅率(TIMI 血流2级或3级),r-Sak 组明显高于 rt-PA 组(77.8%比63.6%,P=0.0277),TIMI 3级者两组间差异无统计学意义(57.6%比48.5%,P=0.1929);1个月内死亡(8.7%比5.7%,P=0.3997)、非致死性再梗死(2.9%比3.8%,P=1.0000)、心肌缺血复发(8.7%比16.0%,P=0.1043)和复合临床终点(18.3%比21.7%,P=0.5345)两组间差异均无统计学意义。次要终点:r-Sak 组出血发生率(28.8%)与 rt-PA组(27.4%)比较,差异无统计学意义(P=0.8105),其中严重或威胁生命的出血,两组间差异亦无统计学意义(1.9%比3.8%),r-Sak 组脑出血1例(0.96%),rt-PA 组脑出血4例(3.85%)。无其他药物相关的严重不良反应及过敏反应发生。结论 r-Sak 是一种安全、有效的治疗 AMI 的溶栓药物,其疗效及安全性至少与 rt-PA 50 mg 相似。 | Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction | 2007 | 中华心血管病杂志2007，35，8： | 43 |
| 8 | 女性急性心肌梗塞的临床特点显示文摘目的为了解女性急性心肌梗塞(AMI)的临床特点,以提高防治效果。方法对北京地区防治冠心病协作组1990~1991年连续收治的1614例患者(男1185,女429),进行男女比较分析。根据患者年龄分为(<45,45~54,55~64,≥65岁)四组,比较患者例数、并发症及病死率。结果四组男与女患者比例分别为17.8:1,6.1:1,3.2:1和1.8:1。女性并发心源性休克者明显多于男性。发病4周病死率,女性14.7%明显高于男性9.4%。在45~54岁组内,差异亦有显著性(1.2%比0.7%)。结论提示与年龄有关的雌激素水平变化对女性AMI临床特点有明显的影响。 | Beijing Collaborative Study Group of Coronary Heart Disease 100700 (correspondewce: Beijing General Hospital, PLA, Beijing 100700) | 1998 | 中华心血管病杂志1998，26，3： | 47 |
| 9 | 卡托普利对前壁与下壁心肌梗塞作用差异的临床试验显示文摘报告中国转换酶抑制剂治疗急性心肌梗塞多中心随机双盲安慰剂对照临床试验的一部分,重点探讨卡托普利对前壁与下壁心肌梗塞作用的差异。选择急性心肌梗塞患者12631例,随机分配到卡托普利治疗组或安慰剂对照组,口服卡托普利或安慰剂12.5mg3次/d,治疗4周。结果提示:前壁梗塞(n=6057)治疗组4周病死率(9.2%)明显低于对照组(10.8%),减少死亡危险15%(P=0.04),但下壁梗塞(n=3990)病死率治疗组(7.2%)与对照组(6.7%)差异无显著性(P=0.54)。发病6h内入选前壁梗塞病死率治疗组(9.5%)显著低于对照组(13.2%)(P=0.004),但下壁无此差异。非心动过缓(心率≥60次/分)者总病死率治疗组(9.5%)明显低于对照组(11.5%;P=0.04),在前壁尤为显著(治疗组8.6%;对照组12.5%,P=0.001)。结果表明:卡托普利早期治疗前壁心肌梗塞是安全和有益的,但对下壁则无益。 | (Chinese CEI-AMI Clinical Trial Collaboration Group)(Correspondence: Department of Hypertension, Fu Wai Hospital, CAMS, 100037 Beijing, China) | 1995 | 中华心血管病杂志1995，23，3： | 19 |
| 10 | Multimorbidity patterns and association with mortality in 0.5 million Chinese adults显示文摘Background:Few studies have assessed the relationship between multimorbidity patterns and mortality risk in the Chinese population.We aimed to identify multimorbidity patterns and examined the associations of multimorbidity patterns and the number of chronic diseases with the risk of mortality among Chinese middle-aged and older adults.Methods:We used data from the China Kadoorie Biobank and included 512,723 participants aged 30 to 79 years.Multimorbidity was defined as the presence of two or more of the 15 chronic diseases collected by self-report or physical examination at baseline.Multimorbidity patterns were identified using hierarchical cluster analysis.Cox regression was used to estimate the associations of multimorbidity patterns and the number of chronic diseases with all-cause and cause-specific mortality.Results:Overall,15.8%of participants had multimorbidity.The prevalence of multimorbidity increased with age and was higher in urban than rural participants.Four multimorbidity patterns were identified,including cardiometabolic multimorbidity(diabetes,coronary heart disease,stroke,and hypertension),respiratory multimorbidity(tuberculosis,asthma,and chronic obstructive pulmonary disease),gastrointestinal and hepatorenal multimorbidity(gallstone disease,chronic kidney disease,cirrhosis,peptic ulcer,and cancer),and mental and arthritis multimorbidity(neurasthenia,psychiatric disorder,and rheumatoid arthritis).During a median of 10.8 years of follow-up,49,371 deaths occurred.Compared with participants without multimorbidity,cardiometabolic multimorbidity(hazard ratios[HR]=2.20,95%confidence intervals[CI]:2.14-2.26)and respiratory multimorbidity(HR=2.13,95%CI:1.97-2.31)demonstrated relatively higher risks of mortality,followed by gastrointestinal and hepatorenal multimorbidity(HR=1.33,95%CI:1.22-1.46).The mortality risk increased by 36%(HR=1.36,95%CI:1.35-1.37)with every additional disease.Conclusion:Cardiometabolic multimorbidity and respiratory multimorbidity posed the highest threat on mortality risk and deserved particular attention in Chinese adults. | Junning Fan Zhijia Sun Canqing Yu Yu Guo Pei Pei Ling Yang Yiping Chen Huaidong Du Dianjianyi Sun Yuanjie Pang Jun Zhang Simon Gilbert Daniel Avery Junshi Chen Zhengming Chen Jun Lyu Liming Li On Behalf of the China Kadoorie Biobank Collaborative Group | 2022 | Chinese Medical Journal2022，，6： | 17 |
| 11 | Exocrine pancreatic insufficiency in adults:A shared position statement of the Italian association for the study of the pancreas显示文摘This is a medical position statement developed by the Exocrine Pancreatic Insufficiency collaborative group which is a part of the Italian Association for the Study of the Pancreas(AISP).We covered the main diseases associated with exocrine pancreatic insufficiency(EPI)which are of common interest to internists/gastroenterologists,oncologists and surgeons,fully aware that EPI may also occur together with many other diseases,but less frequently.A preliminary manuscript based on an extended literature search(Medline/PubMed,Cochrane Library and Google Scholar)of published reports was prepared,and key recommendations were proposed.The evidence was discussed at a dedicated meeting in Bologna during the National Meeting of the Association in October 2012.Each of the proposed recommendations and algorithms was discussed and an initial consensus was reached.The final draft of the manuscript was then sent to the AISP Council for approval and/or modification.All concerned parties approved the final version of the manuscript in June 2013. | Raffaele Pezzilli Angelo Andriulli Claudio Bassi Gianpaolo Balzano Maurizio Cantore Gianfranco Delle Fave Massimo Falconi Luca Frulloni the Exocrine Pancreatic Insufficiency collaborative(EPIc) Group | 2013 | World Journal of Gastroenterology2013，19，44： | 16 |
| 12 | 流脑流行与人群抗体水平及带菌状况关系之探讨显示文摘通过80年代流脑流行周期的系统观察,首次阐明流脑流行与人群抗体水平及带菌状况之相关关系。观察结果显示,当流脑疫情处于散发期,流脑发病率及人群带菌率均处于低水平,人群流脑抗体水平也随之下降。当抗体水平降到低水平时。人群带菌率、流脑发病开始上升.然后抗体水平也随之升高.使用A群脑膜炎多糖菌苗免疫人群后,抗体水平显著上升,流脑发病、人群带菌明显下降。了解了这种变化规律,可早期观察流脑流行趋势,有利于采取各种防疫措施,指导流脑菌苗的接种工作,提高菌苗接种的经济效益。 | WuGuei kuen et al,(Collaboration Group of 7 Provincial Sanitary and Anti-epidemic Stations and Institute of Epidemiology and Microbiology(Beijing 100000) | 1994 | 中国公共卫生学报1994，13，4： | 6 |
| 13 | Oral captopril versus placebo among 14962 patients with suspected acute myocardial infarction: a multicenter,randomized,double-blind,placebo controlled clinical trial显示文摘Oralcaptoprilversusplaceboamong14962patientswithsuspectedacutemyocardialinfarction:amulticenter,randomized,double┐blind,place... | Chinese Cardiac Study (CCS 1) Collaborative Group | 1997 | Chinese Medical Journal1997，，11： | 5 |
| 14 | Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes显示文摘 | The ADVANCE Collaborative Group | | New England Journal of Medicine0，，： | 3 |
| 15 | Tamoxifen for early breast cancer: An overview of the randomized trials显示文摘 | Early Breast Cancer Trialists Collaborative Group | 1998 | Lancet1998，351，： | 2 |
| 16 | Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials显示文摘 | Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) | 2012 | 2012 (9814)2012，，9814： | 2 |
| 17 | Pandemic influenza 2009: Impact of vaccination coverage on critical illness in children, a Canada and France observational study显示文摘AIM To study the impact of vaccination critical illness due to H1N1pdm09, we compared the incidence and severity of H1N1pdm09 infection in Canada and France.METHODS We studied two national cohorts that included children with documented H1N1pdm09 infection, admitted to a pediatric intensive care unit(PICU) in Canada and in France between October 1, 2009 and January 31, 2010.RESULTS Vaccination coverage prior to admission to PICUs was higher in Canada than in France(21% vs 2% of children respectively, P < 0.001), and in both countries, vaccination coverage prior to admission of these critically ill patients was substantially lower than in the general pediatric population(P < 0.001). In Canada, 160 children(incidence = 2.6/100000 children) were hospitalized in PICU compared to 125 children(incidence = 1.1/100000) in France(P < 0.001). Mortality rates were similar in Canada and France(4.4% vs 6.5%, P = 0.45, respectively), median invasive mechanical ventilation duration and mean PICU length of stay were shorter in Canada(4 d vs 6 d, P = 0.02 and 5.7 d vs 8.2 d, P = 0.03, respectively). H1N1pdm09 vaccination prior to PICU admission was associated with a decreased risk of requiring invasive mechanical ventilation(OR = 0.30, 95%CI: 0.11-0.83, P = 0.02).CONCLUSION The critical illness due to H1N1pdm09 had a higher incidence in Canada than in France. Critically ill children were less likely to have received vaccination prior to hospitalization in comparison to general population and children vaccinated had lower risk of ventilation. | Olivier Fléchelles Olivier Brissaud Robert Fowler Thierry Ducruet Philippe Jouvet the Pediatric Canadian Critical Care Trials Group H1N1 Collaborative and Groupe Francophone de Réanimation et Urgences Pédiatriques | 2016 | World Journal of Clinical Pediatrics2016，5，4： | 2 |
| 18 | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial显示文摘 | Heart Protection Study Collaborative Group | | The Lancet0，，： | 2 |
| 19 | Adjuvant radiotherapy for rectal cancer:a systematic overview of 8507 patients from 22 randomised trials显示文摘 | Colorectal Cancer Collaborative Group | | The Lancet0，，： | 2 |
| 20 | Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial显示文摘 | FOxTROT Collaborative Group | 2012 | Lancet Oncology2012，，11： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员